← Leaderboards
David E Avigan
Beth Israel Deaconess Medical Center
$5,917,131
Attributed
$7,788,104
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,788,104 · 6
By mechanism
R01$6,946,602 · 3
R21$841,502 · 2
M01$0 · 1
Top collaborators
- Jacalyn Rosenblatt4 shared
- Simon C Robson2 shared
- Joel Voldman1 shared
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Keisuke Ito$9,818,052
- Dong-Er Zhang$30,254,830
- Vassiliki A Boussiotis$19,288,605
- Mark L Andermann$16,810,308
- Jacalyn Rosenblatt$2,179,647
Others in their field
Top investigators on “Toxic Effect”
- George R Seage · Abt Associates, Inc.$224,114,540
- Peter C Adamson · National Childhood Cancer Foundation$126,756,857
- Gregory H Reaman · National Childhood Cancer Foundation$123,836,183
- Carol Nesel · Westat$116,355,411
- Mary M Horowitz · Medical College Of Wisconsin$90,165,506
- Barney Sparrow · Battelle Memorial Institute$88,494,220
Research focus
Toxic EffectResponseNeoplastic CellVaccinesPathway InteractionsLeukemiaTumorMediatingAntigensPreventImmuneDisease RemissionElementsT-LymphocyteBone MarrowCharacteristicsClinical ResearchPhenotypeRelapseHeterogeneityAreaAutologousCell FusionChemotherapy
Grant awards (19)
Personalized Adoptive T-cell Therapy for AML$728,501
R01 · FY2025 · CA · contact PI
Personalized Adoptive T-cell Therapy for AML$692,077
R01 · FY2024 · CA · contact PI
Personalized Adoptive T-cell Therapy for AML$717,103
R01 · FY2022 · CA · contact PI
Personalized vaccine for patients with AML$653,338
R01 · FY2022 · CA · contact PI
Personalized Adoptive T-cell Therapy for AML$762,763
R01 · FY2021 · CA · contact PI
High-efficiency microfluidic cell fusion for dendritic cell/tumor cell vaccine production$428,524
R21 · FY2021 · CA
Personalized vaccine for patients with AML$54,507
R01 · FY2021 · CA · contact PI
Personalized vaccine for patients with AML$721,179
R01 · FY2020 · CA · contact PI
Targeting PML for Leukemia Therapy$456,984
R01 · FY2020 · CA · contact PI
Personalized vaccine for patients with AML$699,542
R01 · FY2019 · CA · contact PI
Directed Purinergic Signaling as Immunotherapy in Leukemia$184,603
R21 · FY2019 · CA
Personalized vaccine for patients with AML$721,179
R01 · FY2018 · CA · contact PI
Directed Purinergic Signaling as Immunotherapy in Leukemia$228,375
R21 · FY2018 · CA
Personalized vaccine for patients with AML$739,429
R01 · FY2017 · CA · contact PI
POST TRANSPLANT RHIL 12--BREAST CANCER THERAPY$0
M01 · FY2002 · RR
POST TRANSPLANT RHIL 12--BREAST CANCER THERAPY$0
M01 · FY2001 · RR
POST TRANSPLANT RHIL 12--BREAST CANCER THERAPY$0
M01 · FY2000 · RR
POST TRANSPLANT RHIL 12--BREAST CANCER THERAPY$0
M01 · FY2000 · RR
POST TRANSPLANT RHIL 12--BREAST CANCER THERAPY$0
M01 · FY2000 · RR